Hyloris Pharmaceuticals prepared to go public
Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
NodThera bags US$55m in Series B round
NodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
Bacterial colonisation differs by tumour type
An analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
Novo Holdings invests into AI CRO ExScientia
Poxel SA raises 17.7m through capital increase
Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at 0.02 per share reserved to specified investors.
British scientists start Phase II on COVID-19 vaccine
Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
New algorithm predicts rheumatoid arthritis
Based on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
SARS-CoV2 antibody tests: not suited for individual diagnosis?
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Vaccine to protect from any viral infection
Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
Abivax bags 36m fund for COVID-19 programme
French Abivax SA has received a 36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.